Actavis has a world-leading position in innovative treatments for disorders of the central nervous system (CNS), including neurological and neurodegenerative diseases, pain, and movement disorders, as well as a strong portfolio of products to address respiratory disease, including asthma, allergic rhinitis, and chronic obstructive pulmonary disease (COPD).

Across its specialty medicines portfolio, Actavis focuses on developing, personalizing and improving treatment of disorders for patients in CNS, respiratory, oncology, and select local/regional therapeutic areas. Actavis integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies.

Learn more about each of our key therapeutic areas >